BioOutsource to Host Webinar on Biosimilar Comparability on Thursday, 12 February

Free Webinar to Explore Comparability Challenges Faced by Developers of Biosimilars GLASGOW, Scotland and CAMBRIDGE, Mass. – 9 February 2015 – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterization for the biopharmaceutical industry, today announced that it will be hosting a free webinar on Thursday, 12 February, at 3:00 p.m. More

BioOutsource Ramps up Investment in R&D to Prepare for Biosimilars Boom

Already a Leader in Comparability of Biosimilars, New R&D Initiative Aligns BioOutsources’ Strategy with the Next Generation of Biosimilars, to Support Client Testing Requirements and Leverage Rapid Growth in Biosimilars Market GLASGOW, Scotland and CAMBRIDGE, Mass. – 3rd November 2014 – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterisation for More

GEN Exclusives – Animal Testing: Hard choices loom as Biosimilars boom

The approaching biosimilars tidal wave puts the question of animal testing for biologics further under scrutiny. Read our Chief Scientific Officer, Dr Daniel Galbraith’s article in GEN Exclusives. Follow this link to read the full article. For more detail on this issue, read our team’s position paper: Adventitious agent testing using in vivo protocols: A BioOutsource Position More

Biosimilars Awaken CROs

CSO, Dr Daniel Galbraith’s article on how biosimilars have prompted CROs to be more flexible and for developers to seek focused, niche testing partners.

PsiOxus select BioOutsource to support clinical sample analysis for OCTAVE ovarian cancer study

GLASGOW, Scotland. – 19 June, 2014 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organisation (CTO) today announced their partnership with PsiOxus Therapeutics Ltd. to support clinical sample analysis of their Phase I/II OCTAVE (Ovarian Cancer) study. PsiOxus Therapeutics, Ltd., an Oxford, based biotechnology company, has been awarded a £1.7 million grant towards a Phase More

BioOutsource expands ADC characterisation capabilities

A global leader in ADC characterisation, BioOutsource, partners with Glythera. Exhibits at World ADC Summit in Frankfurt. GLASGOW, Scotland.  – 18 February 2014 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has amplified its position as a global leader inAntibody Drug Conjugates (ADC) characterisation and are pleased to announce a partnership with More

BioOutsource to Open New Biosimilar Centre of Excellence in Glasgow as Global Demand Surges

Already a Leader in Biosimilar Services, Company’s Biosimilars Analysis Capacity to Double with Addition of New Facility Glasgow, Scotland, February 5, 2014 , BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterization for the biopharmaceutical industry, today announced the opening of a new Biosimilar Centre of Excellence in Glasgow. The new More

BioOutsource Launches Comprehensive Range of Off-the-Shelf Testing Methodologies to Support Biosimilar Characterisation & Comparability Testing

Expands Glasgow, Scotland Testing Facilities and Ramps up Commercial Activities in US and Asia-Pacific GLASGOW, Scotland – September 20, 2013 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has consolidated its position as the leading expert in the biological analysis of Biosimilar Monoclonal Antibodies for the biopharmaceutical industry. Strategic internal R&D investment More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.